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Imaging of dialysis-related amyloid (AB-amyloid) deposits with '3'I-2-
microglobulin. The diagnosis of dialysis-related amyloid (AB-amyloid)
has been based usually on clinical and radiological criteria. Following
the discovery that 132-microglobulin was the major protein of this
amyloid, we isolated and radiolabelled uremic plasma /32-microglobulin.
After intravenous injection, gamma-camera images of selected joint
areas were obtained from 42 patients who were on regular hemodialysis
therapy. Positive scans involving the shoulder, hip, knee and carpal
regions were found in 13 of 14 patients treated for more than 10 years
and 10 of 16 patients treated for 5 to 10 years. Patients treated for less
time had negative scans. Specificity was indicated by negative scans in
non-amyloid inflammatory lesions in control hemodialysis patients. Up
to 48-fold tracer enrichment was detected in excised AB-amyloid
containing tissue as compared to amyloid-free tissue. These findings
suggest that circulating radiolabelled /32-microglobulin is taken up by
the amyloid deposits. This method may non-invasively detect tissue
infiltrates of amyloid. It may also permit prospective evaluation of the
efficacy of prophylactic dialysis strategies which are designed to pre-
vent or delay the onset of this complication of long-term dialysis.
Dialysis related amyloidosis (AB-amyloidosis) has become a
major complication of long-term dialysis therapy. Its preva-
lence in patients on treatment for more than 10 years is
estimated to vary from 30 to 100% [1—41. The specificity of
AB-amyloid was established in 1985, when 2-microglobulin
was identified as the major protein present in the fibrils of the
amyloid tissue which was obtained from two hemodialysis
patients either during carpal tunnel surgery [5] or during surgery
for a juxta-articular radiolucent cystic bone lesion [61. Since
then, the diagnosis mainly has been made on clinical and
radiological grounds, which are based upon the presence of the
carpal tunnel syndrome and/or juxta-articular radiolucent cystic
bone lesions in both long-term hemodialysis and peritoneal
dialysis patients [1—4]. Systemic manifestations, especially in
regard to organs, are rare [1, 2]. Consequently, invasive diag-
nostic procedures commonly used to diagnose other types of
amyloid, such as rectal biopsy, fat aspiration or skin biopsy,
yield negative results in the majority of these patients [1, 2, 7,
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8]. The specific diagnosis has required confirmation from tissue
obtained by bone or synovial biopsy or at autopsy.
Previous attempts to diagnose AB-amyloid by radiodiagnos-
tic tests, such as mTctagged phosphates, have failed [1, 4, 9,
10]. Recently, a more specific radiodiagnostic test, using serum
amyloid P component labelled with 1231 was demonstrated to
detect the amyloid fibril ligand for this protein [11]. In a
preliminary report, we described the enrichment of intrave-
nously injected '311-labelled human f32-microglobulin in a sub-
cutaneous AB-amyloid nodule of a long-term hemodialysis
patient [12]. In addition, in three long-term hemodialysis pa-
tients on treatment for more than 10 years with biopsy-proven
AB-amyloid, we demonstrated a positive scan of the hips,
knees and shoulders. In one hemodialysis patient on treatment
for six months the scan was negative [12].
The purpose of this study was to evaluate 42 hemodialysis
patients selected on a treatment time basis between 0.5 and 18
years in order to determine the positivity of their scans in
relation to time on dialysis. A further goal was to demonstrate
the specificity of the scan.
Methods
Isolation, characterization and radiolabelling of 132-
micro globulin
J32-microglobulin, obtained from the plasma ultrafiltrate of a
HIV-I-, HIV-II-, HBsAg-negative uremic patient with persis-
tently normal liver enzymes, was purified under sterile condi-
tions as described in detail elsewhere [13]. When the final
product, after lyophilization and storage at —20°C, was charac-
terized by column chromatography (Sephadex G 75 SF; Phar-
macia, NUrnberg, FRG), SDS-PAGE electrophoresis and
immunoblotting as described in detail elsewhere [14], no con-
taminating proteins were detected. The product was found to
contain more than 99% monomeric f32-microglobulin as well as
less than 1% of apparently dimeric 3.2-microglobulin [14].
Immunoblotting of the purified 132-microglobulin revealed a
minor contamination of a /32-microglobulin reactive molecule
with an apparent molecular weight of 17.6 kDa. This contami-
nation seemed to represent "modified" f32-microglobulin [14,
15].
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To evaluate the effect of labelling on the purified molecule,
sham-labelling was performed using the Chioramine T method
[161. SDS gel electrophoresis and immunoblotting did not
indicate that labelling of the purified /32-microglobulin caused
significant alterations of the molecule [14]. Gel chromatogra-
phy, however, showed that the relative contribution of dimeric
f32-microglobulin had increased after labelling to less than 10%
[141. In addition, less than 5% of the labelled molecules were
detected in high molecular weight fractions (exclusion volume)
of the gel column, which may be due to even higher degrees of
polymerization or due to binding of the label to albumin [14].
For each scan 0.1 mg of the purified f32-microglobulin was
labelled with 370 MBq of Na131! (IBS.30, Amersham, Braun-
schweig, FRG) using the Chloramine T method [16], followed
by purification, sterilization and pyrogen-removal as described
elsewhere [12]. Over 97% of the radioactivity of the final
preparations could be precipitated with trichloroacetic acid
(TCA; final concentration 15% vol/vol). Immunological reactiv-
ity of the labelled /32-microglobulin was not altered [14]. Ali-
quots of all final '311-f32-microglobulin preparations were sub-
mitted to Sephadex G 75 SF gel chromatography before
injection to check their composition. All preparations were
used within five days of radiolabelling.
Patients
Forty-two patients (12 females, 30 males; mean age 50 12
years, range 25 to 80 years) on chronic hemodialysis for
between 0.5 to 18 years were studied. Written informed consent
to the protocol was obtained. Injection of the radiolabelled
protein was approved by the ethics committee of the Hannover
Medical School. All patients had a residual creatinine clearance
below 2 mllmin and residual diuresis was less than 250 mllday.
Within one month of performing the '31I-2-microglobulin scan,
X-ray images of the hands, shoulders, pelvis and knees were
obtained from every patient. Juxtaarticular, cystic radiolucen-
cies with a diameter more than 5 mm or radiological signs of
humeroscapular periarthritis were considered to be compatible
with the presence of AB-amyloidosis. All patients were evalu-
ated clinically for a history or presence of carpal tunnel syn-
drome, tenosynovitis, destructive arthropathy with or without
recurrent joint effusions or humeroscapular periarthritis.
Tissue was obtained from nine patients during surgery or at
autopsy either before or within one year after the scan. All
tissue samples were examined by histology, immunohistology
and electronmicroscopy for the presence of AB amyloid, as
described in detail elsewhere [17].
'311-132-micro globulin radiodia gnostic imaging
Prior to injection, thyroidal uptake of free iodine was blocked
in every patient by the administration of sodium perchiorate
[12]. The study was initiated by intravenous injection of approx-
imately 20 g radiolabelled /32-microglobulin, corresponding to
60 MBq in anuric patients. In patients with a preserved residual
diuresis 25 pg (70 MBq) were injected to partly compensate for
the renal tracer elimination during the study period. The result-
ing radiation absorbed doses were calculated as 11 to 15 mSv
(whole body) or 13 to 17 mSv (red bone marrow, testes). At
about 24-hours post-injection a Cuprophan® hemodialysis was
performed. For the subsequent treatment, a hemo(dia)filtration
with a highly permeable polysulphone hemodialyzer (HF 60,
Fresenius, FRG) was undertaken. Seventy-two to 96 hours
alter injection, gamma-camera images [12] were obtained of the
shoulders, pelvis and lower vertebral column, knees and hands.
In addition other areas of the body were scanned as required.
Due to patient-related problems no images were obtained of the
knees of patients #27, 40 and 42, as well as of the shoulders of
patients 40 and 42. Furthermore, due to initial technical prob-
lems sufficient had images were only obtained in patients 10, 16,
and 20 to 42. All scans were qualitatively evaluated by a
radiologist in the Department of Nuclear Medicine (W.B.), who
was not aware of patient data. Local tracer accumulation was
defined as an area of relative increase of radioactivity above
background, which could not be explained by either an increase
of tissue thickness or by radioactivity associated with the
intravascular pool.
Tracer accumulation or clinicallradiological symptomatology
was graded according to the number of sites involved as "0"
(none), "I" (I or 2 sites), "II" (3 or 4 sites), "III" (5 or 6 sites)
and "IV" (>6 sites).
Examinations of tissues excised after injection of '"-f32-
microglobulin
In four patients tissue could be obtained during surgery or
autopsy within 4 to 10 days of the injection of radiolabelled
/32-microglobulin. If AB-amyloid deposits were detected histo-
logically [17], the radioactivity of this tissue was compared to
the radioactivity in surrounding fat, muscle and subcutaneous
tissue or in plasma samples obtained simultaneously. Thereaf-
ter, the tissue specimens were homogenized in PBS buffer (pH
7.4) and protein was then precipitated with TCA (final concen-
tration 15% vol/vol, 30 mm, 4°C). After centnfugation and
repeat washing with TCA, the radioactivity in the pellet and
supernatant was determined.
In patient 15, a postmortem in vitro image of an amyloid-
infiltrated hip was obtained by gamma camera scanning. Alter-
natively, in two cases, histological autoradiographic imaging of
amyloid-infiltrated tissue (obtained at 4 and 9 days, respec-
tively, after tracer injection) was attempted on 6 to 8 sm
sections using standard techniques [18].
In patient 6 AB-amyloid fibrils were isolated from excised
synovial tissue using the method described by Pras et al [191.
Briefly, amyloid tissue was homogenized at 4°C in 0.15 MNaCI
and then centrifuged for 30 minutes at 10,000 rpm. The super-
natant (#1) was then removed and the sediment resuspended,
homogenized in 0.15 M NaC1 and again centrifuged for 30
minutes at 10,000 rpm. This procedure was repeated six times
(supernatants #2 to 7). Thereafter, the sediment was homoge-
nized in distilled water and centrifuged for 60 minutes at 30,000
rpm. After removing the supernatant (#8) this procedure was
repeated three times (supernatants #9 to 11). Following this,
the total and TCA-precipitable radioactivity were determined
for each supernatant and for the final sediment. After the
addition of 0.1 M NaCI, Congo red staining of dried aliquots of
supernatants #8 to 11 confirmed the presence of amyloid in
these supernatants. As a control, amyloid-free fat and muscle
tissue was treated in an identical manner.
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to 10 years treatment to 100% at 15 to 20 years (Fig. 3). The
number of tracer accumulation sites was also correlated with
the time on treatment and increased from 12.5% grade IV scans
at 5 to 10 years to 80% at 15 to 20 years (Fig. 3). No correlation
of the patients age with tracer accumulations evolved from the
data of this study, when either all patients or only patients
between 5 and 10 years of treatment were analyzed.
Concerning the reproducibility of the scans, an almost iden-
tical '311-/32-microglobulin scan was obtained in patient 6 after
nine months (Fig. 2). Furthermore, scans positive at 48 hours
after injection reproduced at 144 hours when '311-f32-microglob-
ulin was used (Fig. 4). In contrast, it was impossible to obtain a
positive scan in our preliminary studies at 24 hours after
injection. Also, due to the short tracer half life, no positive scan
could be obtained after the injection of '231-labelled /32-micro-
globulin in a patient on chronic hemodialysis for 14 years with
advanced AB-amyloidosis.
Transient partial outlines of the large intestine were observed
in 19% of the scans. At 96 hours after tracer injection, fecal
enrichment of radioactivity was noted (57, 185 35,484
counts/g as compared to 15,575 10,477 counts/mI whole
blood). If a residual diuresis was present, transient tracer
accumulation was occasionally noted over the bladder region.
As these sites probably represent pathways of elimination of
1311-132-microglobulin or derived products, they were neglected
for scan evaluation. In addition, as free radiolodine may accu-
mulate in the salivary glands, thyroid and stomach, these sites
were also neglected for scan evaluation.
Due to renal tracer excretion in patients with preserved
residual diuresis, local tracer accumulations tended to be
weaker in these patients. In an attempt to compensate for this,
higher tracer doses (Methods) were injected in such patients and
longer gamma camera imaging was performed. Besides the
correlation of the intensity of tracer uptake with residual renal
function, no correlation of the intensity with the presence or
absence of clinical symptoms was observed.
No side effects or adverse reactions attributable to the
injection of '31I-32-microglobulin were observed,
Morphological correlates of '31I-32-microglobu!in
Fig. 1. Representative images obtained after in vivo injection of J3Jj
/32-microglobu!in. A. Dorsal image at 72 hours after tracer injection of
the shoulders/neck of patient 3 in whom clinical and radiological signs
of a left-sided humeroscapular periarthritis were present. B. Dorsal
image of the pelvic area of patient 6 at 72 hours after tracer injection
showing local accumulation in both hip regions, pelvic sites and over
the lumbar vertebral column. Clinically and radiologically a cystic




Localized tracer accumulations (positive scan: grades Ito IV)
were found in 23 of 42 hemodialysis patients studied. Sites of
local tracer accumulation included the shoulders (Fig. IA),
pelvis/hips (Fig. IB), vertebral column (Fig. IB), knees (Fig. 2)
and carpal regions. Patients treated for less than five years had
no localized tracer accumulations (negative scan: grade 0) (Fig.
3). The prevalence of scan positivity increased from 62.5% at 5
radiodia gnostic images
In patient 15, who died of a cerebral hemorrhage at 10 days
after the scan, an autoradiographic in vitro image of the left hip
(Fig. SA) showed that the tracer accumulation noted in vivo was
confined to the joint capsule and the juxtaarticular bones, while
no accumulation was present in the remaining part of the femur.
At autopsy two AB-amyloid "cysts" in the neck of the femur
and synovial AB-amyloid deposits were detected (Fig. SB).
In three patients, tissue was obtained during surgery at 4 to 10
days after tracer injection. As shown in Table 1, up to 48-fold
enrichment of the tracer was noted in amyloid-tissue as com-
pared to adjacent, amyloid-free tissue. No increase of radioac-
tivity over that measured in plasma occurred in synovial fluid
despite massive amyloid infiltration of the synovial membrane.
Attempts to obtain an autoradiographic image of histological
amyloid tissue sections, obtained at four and nine days after
tracer injection,, failed despite prolonged exposure of the pho-
tographic emulsion.
When amyloid fibrils were extracted from I g of the amyloid-
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Fig. 2. Ventral image (72 hours after
injection of the label) of the knees of patient 6
in November 1988 and during a repeat scan in
August 1989. In August 1989 a synovectomy
of the left knee was performed for recurrent
joint effusion and a recurrent Baker cyst.
Histologically massive AB-amyloid infiltration
of the synovia and cyst wall was detected.
Fig. 3. Presence of '311-132-microglobulin accumulations in hemodial-
ysis patients versus clinical and/or radiological findings compatible
with the diagnosis of AB-amyloidosis. Tracer accumulation observed in
the liver of patients 41 and 42 (AA-amyloidosis) was neglected in this
classification. Scan grades are: (Li) — 0, (D) — 1, () — II, () — III,
• - Iv.
tracer injection, and compared to 4.3 g fat and muscle tissue
treated in an identical manner, 255 counts (100% TCA precip-
itable) were detected in the amyloidfibril-containing superna-
tants #8 to 11 as compared to 14 counts/g starting material in
supernatants #8 to 11 of the control tissue.
Sensitivity of '311-/32-micro globulin radiodia gnostic images
In nine patients it was possible to correlate scan findings with
histological findings. While in eight patients local tracer accu-
mulations were detected in areas of amyloid deposits (vide
infra), in one patient (number 35) on hemodialysis for 6.5 years,
five months before death the scan was negative. However, at
autopsy, although the synovial membranes had normal macro-
scopic appearances, there was moderate microscopic AB-
amyloid infiltration in the synovial membrane of the hip and
shoulder joints.
The number of involved predilection sites as judged by
scanning was two-fold higher than as judged by combined
clinical and radiological evaluation (Fig. 3; Table 2).
Specificity of '311-/32-microglobu!in radiodia gnostic images
In three patients with positive scans, seven sites (one corre-
sponding to a site with a radiological abnormality) showed
tracer accumulations, while three further sites with clinical or
radiological abnormalities were not associated with tracer ac-
cumulations (Table 2). In patient 14, with obvious secondary
hyperparathyroidism, a single cystic bone radiolucency in the
right hip was observed, while tracer accumulation was re-
stricted to an extraskeletal calcification (vide infra). In patient
24, a left-sided humeroscapular periarthritis was found, while
local tracer accumulation was confined to the knees. In patient
25, cystic bone radiolucencies of both lateral edges of the
acetabulum were noted, while tracer accumulation was re-
stricted to the left hip area. In all three patients, there was no
biopsy confirmation of the respective area nor of other AB-
amyloid predilection sites available.
The presence of AB-amyloidosis at prior tracer enrichment
sites was (immuno-) histologically confirmed by biopsy or
autopsy in 12 sites of eight patients. No prior scan positive site
was found to lack amyloid deposits upon histological examina-
tion.
No local enrichment was seen when free 'i was used for
scanning in patient 10 eight weeks after a positive I-J-
microglobulin scan. In patient 29, who died nine months fol-
lowing a negative scan, autopsy showed a synovial AB-amyloi-
dosis. Retrospective chromatographic analysis (accidentally
omitted in this instance immediately following iodination)
showed that the injected '311-/32-microglobulin had aggregated
(molecular weight > 75 kDa).
No local tracer enrichment at the respective site of disease
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Fig. 4. Left lateral images of the pelvic area
of patient 2 at 48 and 144 hours after injection
of the label showing increased radioactivity
over the hip area (arrow; containing a cystic
bone radiolucency in the neck of the femur)
and over a subcutaneous AB-amyloid tumor
(asterisk) overlying the ischiac bone (17].
Fig. 5. A. In vitro image of the left hip (pelvic joint parts and proximal
half of the femur including the joint capsule) of patient 15 after the
autopsy 9 days after injection of '311-/32.microglobulin (right) and
negative image of the same specimen, obtained by placing a homoge-
nous radiation source behind the specimen (left). B. Macroscopic view
of the autopsy specimen after transverse sectioning, showing two
(histologically confirmed) AB-amyloid "cysts" in the neck of the femur
(arrows) as well as marked amyloid infiltration of the synovial mem-
brane (asterisks).
occurred in patients with various inflammatory disorders,
which were unrelated to AB-amyloidosis (Table 3). In patients
41 and 42, with a biopsy-proven AA-amyloidosis, a weak image
of the liver was obtained, which persisted during a repeat scan
at 144 hours after injection. In two other patients with a
suspected AL- or AA-amyloidosis, no local tracer accumulation
was noted (Table 3). In several patients minor or moderate
radiological signs of degenerative joints disease (osteoarthritis),
especially in the knees and vertebral column, were noted.
However, no correlation of local tracer accumulations with
these degenerative changes was observed.
In patient 17, who had massive extraskeletal soft-tissue
calcification associated with hyperphosphatemia, local tracer
accumulation was noted only at the sites of the extraskeletal
calcification (Fig. 6). This finding could not be reproduced when
1231 alone was used for scanning. Accumulation of I3II132
microglobulin overlying a single pelvic extraskeletal calcifica-
tion was also detected in patient 14 with obvious secondary
hyperparathyroidism. In neither patient was a histology of the
extraskeletal calcification available.
Prolonged increase of local tissue radioactivity outside of
predilection sites was noted in patients 35 and 40. In patient 35,
it was found in a homogenous pattern over a leg with persistent
postthrombotic edema. In patient 40, it was demonstrated in the
region of lymphatic fistulas surrounding a femoral artery Gore-
tex graft. In the latter patient a similar image was found when
99mTc labelled nanocolloidal human serum albumin (Nanocoll®;
Solco Nuclear, Birsfelden, Switzerland) was used for scanning.
In two additional patients with a biopsy proven AB-amyloi-
dosis, scanning was performed with 99mTc. labelled nanocolloi-
dal human serum albumin (Nanocoll®; Solco Nuclear). No local
enrichment of this tracer around large joints or previously
established sites of AB-amyloid deposition was noted. Also, no
local enrichment of mTclabelled nanocolloidal human serum
albumin was noted at prior '31I-2-microglobulin accumulation
sites in the shoulders or hips of patients 3, 8 and 31.
Discussion
In this study, we demonstrated local accumulations of the
radiolabelled AB-amyloid precursor protein f32-microglobulin in
chronic hemodialysis patients, which were treatment time de-
pendent. A predilection for musculoskeletal and joint regions
was observed in spite of some interindividual variation in the
pattern of accumulation sites. Due to the low energy emission
spectrum of I and probably due to relatively low incorpora-
tion of the tracer into amyloid tissue, attempts to locate the
tracer microscopically failed. However, several findings of this
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Table 1. Specific radioactivity in various tissues obtained at autopsy (patient 15) or during surgery (pati
injection of '311-/32-microglobulin
ents 2, 6, 8) at 4 to 10 days after the
Specific radioactivity counts/,nin/g
Amyloid- Synovial
Pat. tissue Fat Muscle Other sites Plasma fluid
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Numbers in brackets indicate TCA-precipitable radioactivity.
a Subcutaneous amyloid tumor
I) Synovial membrane
Wall of Baker cyst
d Content of cystic bone lesion
C Material obtained from tissue directly adjacent to amyloid-infiltrated synovia
Material contaminated with whole blood
Skin (scattered microscopical amyloid infiltration)
Table 2. Comparison of clinical and radiological findings compatible
with the presence of AB-amyloid with '311--microglobulin scan




Positive scan 21 2
Negative scan 0 19
Sites
Positive scan 56 62
Negative scan 3 171
microglobulin in and around the amyloid fibrils. An enrichment
of the tracer was detected in excised AB-amyloid tissue as well
as in isolated AB-amyloid-fibrils. Tracer accumulations in vivo
depended on the presence of radiolabelled, low-molecular
weight f32-microglobulin rather than on the presence of radio-
iodine or /32-microglobulin aggregates. Additional support for
the specificity of the tracer localization was derived from the
observation that no tracer accumulation occurred at the respec-
tive sites of disease in patients with various inflammatory
disorders unrelated to AB-amyloidosis.
The detection of increased radioactivity in chronic edema
sites or lymphatic fistulas probably reflects the extracellular
distribution volume of '31I-32-microglobulin [14]. The maximal
radioactivity attributable to this non-specific phenomenon was
seen in plasma and synovial fluid. However, this background
radioactivity did not seem to prevent the recognition of specific
tracer accumulation in AB-amyloid predilection sites.
Specific accumulation of '311-132-microglobulin at sites of
amyloid deposition could be attributable to tracer binding to
amyloid fibrils and/or ground substance and/or inflammatory
cells. Tracer binding or incorporation into amyloid fibrils is
suggested by the observed enrichment of radioactivity in iso-
lated AB-amyloid fibrils. Whether this involves intact [6, 7],
modified [20] or fragmented [21] /32-microglobulin remains to be
elucidated. However, the observation of a 48-hour "lag" period
prior to detectable tracer accumulation would be compatible
with a processing step. Binding of the tracer to amyloid fibnls
could also explain the low-grade tracer accumulation in the
livers of two AA-amyloidosis patients, as it is known that small
amounts of other amyloidogenic proteins occur together with
the main amyloid protein [22]. As well as binding to the amyloid
fibrils, the tracer could also bind to ground substance within or
around the amyloid deposits. Apart from glycosaminoglycan
alterations [23] or the collagen binding capacity for /32-micro-
globulin [24], the role of calcium is important. In two patients,
local tracer accumulation was confined to the regions of ex-
traskeletal calcification. It has been speculated that calcium
may act as a nucleus for the formation of AB-amyloid [4, 25],
since AB-amyloid deposition has also been described in hemo-
dialysis patients with cardiac hydroxyapatite calcium deposits
or renal tubular casts containing calcium oxalate [25]. The third
possibility is that the tracer binds to inflammatory cells, espe-
cially macrophages. Such cells are detectable in moderate
numbers in the close vicinity of AB-amyloid fibrils [26]. How-
ever, although these cells have the capacity to bind exogenous
2-microglobulin via an HLA-related mechanism on their cell
surfaces [27], negative scans were obtained in hemodialysis
patients with non-amyloid inflammatory disorders. In addition,
radiolabelled nanocolloidal albumin failed to accumulate at
AB-amyloid sites. The negative scans obtained with this tracer,
a marker of phagocytotic activity [281, suggest that the inflam-
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7 26 F 2 Suspected AL-amyloidosis Negative
22 53 M 5.5 Diabetic foot ulcer Negative
33 54 M 0.5 Bact. infection of renal
cyst
Negative
35 54 M 9 Scrotal abscess, drained Negative




37 27 M 4.5 Primary oxalosis with
coxarthrosis,
Negative





42 62 M 0.2 Biopsy-proven AA-
amyloid
Positivec
a Moderate inflammatory activity at the time of examination
b Positive sites included both shoulders, knees, hips, hands, pelvic sites plus the liver
C Liver only
it may be useful for successive scans of negative patients on
dialysis for less than five years, in order to study the effect of
preventive dialysis strategies on the de novo appearance of
AB-amyloid. In addition, this study demonstrates for the first
time that the uptake of an injected, radiolabelled amyloid
precursor protein into its derived deposits can occur in humans.
It is hoped that it becomes a valuable tool to gain more insight
into the pathogenetic mechanisms underlying the processes
which control in vivo amyloid formation.
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Fig. 6. Ventral image of the knees of patient 17 at 96 hours after tracer
injection showing tracer accumulation confined to an extraskeletal
calcification (arrow).
matory reaction surrounding AB-amyloid deposits is too limited
to be detectable by radiodiagnostic techniques.
Hitherto, the results of retrospective epidemiological surveys
of the prevalence of AB-amyloid based upon clinical and
radiological criteria in relation to dialysis strategies have been
conflicting [29, 30]. Presently, early successful renal transplan-
tation offers the most likely way of preventing this severe
complication of long-term dialysis therapy [30]. The technique
of '311-f32-microglobulin scanning appears to allow the most
sensitive, specific and early diagnosis of AB-amyloidosis non-
invasively. Its future application should enable more accurate
epidemiological studies to evaluate the true prevalence of
AB-amyloidosis. Although the scan does not permit an exact
measurement of the amount of amyloid present at a given site,
Reprint requests to Professor K.M. Koch, Abteilung Nephrologie
6840, Medizinische Hochschule Hannover, 3000 Hannover 61, Federal
Republic of Germany.
References
I. KLEINMANN KS, COBURN JW: Amyloid syndromes associated
with hemodialysis. Kidney mt 35:567—575, 1989
2. BARDIN T, ZINGRAFF J, KUNTZ D, DROEKE T: Dialysis-related
amyloidosis. Nephrol Dial Transplant 1:151—154, 1986
3. CHARRA B, CALEMARD E, LAURENT G: Chronic renal failure
treatment duration and mode: Their relevance to the late dialysis
periarticular syndrome. Blood Purif 6:117—124, 1988
4. RITZ E, BOMMER J, ZEJER M: /32-Mikroglobulin-bedingte Amyloi-
dose. Dtsch Med Wschr 113:190—196, 1988
5. GEYJ0 F, ODANI S, YAMADA T, NAKAGAWA Y, ARAKAWA M,
KUNITOMO T, KATAOKA H, SUZUKI M, HIRASAWA Y, SHIRAI-IAMA
T, COHEN AS, SCHMID K: A new form of amyloid protein associ-
ated with chronic hemodialysis was identified as p2-microglobulin.
Biochetn Biophys Res Commun 129:701—706, 1985
6. GOREVIC PD, CA5Y TT, STONE Wi, DIRAIMONDO CR, PRELLI FC,
FRANGIONE B: p2-microglobulin is an amyloidogenic protein in
man. J Clin Invest 76:2425—2429, 1985
L
1176 Floege et a!: Scanning for dialysis related amy!oidosis
7. VARGAJ, IDELSON B, FELSON D, SKINNER M, COHEN AS: Lack of
amyloid in abdominal fat aspirates from patients undergoing long-
term hemodialysis. Arch Intern Med l47:1455—1457, 1987
8. CAMPISTOL JM, SOLE M, FERRANDO J, PALOU J, MUNOZ-GOMEZ
J, LOPEZ-PEDRET J, REVERT L: Negativeness of skin biopsy in
dialysis amyloidosis. Nephron 48:259—260, 1988
9. GRATEAU 0, ZINGRAFF J, FAUCHET M, MUNDLER 0, RAYMOND P.
BERTHELOT JM, BARDIN T, KUNTZ D, DRUEKE T: Radionuclide
exploration of dialysis amyloidosis: Preliminary experience. Am J
Kidney Dis 9:231—237, 1988
10. SETH! D, NAUNTON MORGAN IC, BROWN EA, JEWKES RF,
GOWER PEr Technetium-99-labelled methylene diphosphonate up-
take scans in patients with dialysis arthropathy. Nephron 54:202—
207, 1990
II. HAWKINS PN, MYERS MJ, LAVENDER JP, PEPYS MB: Diagnostic
radionuclide imaging of amyloid: Biological targeting by circulating
human serum amyloid P component. Lancet 1:1413—1418, 1988
12. FLOEGE J, NONNAST-DANIEL B, GIELOW P. BRANDIS A, SPINDLER
E, HUNDESHAGEN H, KOCH KM. SHALDON S: Specific imaging of
dialysis-related amyloid deposits using '311-p2-microglobulin.
Nephron 51:411—117, 1989
13. Methods to diagnose and treat amyloidoses specifically and sub-
stance therefore. British Patent Application No. 8821342.6
14. FLOEGE J, BARTSCH A, SCHULZE M, SHALDON S. KOCH KM,
SMEBY LC: Clearance and synthesis rates of /32-microglobulin in
hemodialyzed patients and normals. (submitted for publication)
15. FORBES MA, Cox AM, COOPER EH: A method to detect the in vitro
modification of serum /32-microglobulin in health and disease. C!in
C/tim Acta 177:89—100, 1988
16. HUNTER WM, GREENWOOD FC: Preparation of iodine-'31 labelled
human growth hormone of high specific activity. Nature 194:495—
496, 1962
17. FLOEGE J, BRANDIS A, NONNAST-DANIEL B, WESTHOFF-BLECK
M, LINKE RP, KOCH KM: Subcutaneous amyloid tumor of 132-
microglobulin origin in a long-term hemodialysis patient. Nephron
53:73—75, 1989
18. PABST R, STERZEL RB: Cell renewal of glomerular cell types in
normal rats. An autoradiographic study. Kidney mt 24:626—631,
1983
19. Pits M, SCHUBERT M, ZUCKER-FRANKLIN D, RIM0N A, FRANK-
LIN EC: The characterization of soluble amyloid prepared in water.
J Clin Invest 47:924—933, 1968
20. OGAWA H, SAITO A, ODA 0, NAKAJIMA M, CHUNG TG: Detection
of novel /32-microglobulin in the serum of hemodialysis patients and
its amyloidogenic predisposition. Clin Nephrol 30:158—163, 1988
21. LINKE RP, HAMPL H, LOBECK H, RITZ E, BOMMERJ, WALDHERR
R, EULITZ M: Lysine-specific cleavage of 132-microglobulin in
amyloid deposits associated with hemodialysis. Kidney mt 36:675—
681, 1989
22. LINKE RP, NATHRATH WBJ, EULITZ M: Classification of amyloid
syndromes from tissue sections using antibodies against various
amyloid fibril proteins: report of 142 cases, in Amyloidosis, edited
by GLENNER 0, New York, Plenum Press, 1986, p. 599—605
23. KI5ILEvsKY R, SNOW A: The potential significance of sulphated
glycosaminoglykans as a common constituent of all amyloids: or,
perhaps amyloid is not a misnomer. Med Hypotheses 26:23 1—236,
1988
24. HOMMA N, GEYJO F, ISEMURA M, ARAKAWA Mr Collagen-binding
affinity of /32-microglobulin, a preprotein of hemodialysis associated
amyloidosis. Nephron 53:37—40, 1989
25. ARAKAWA M, GEYJO F, OOHARA K, HOMMA N: Systemic deposi-
tion of Beta-2 microglobulin amyloid, in Dialysis Amyloidosis,
edited by GEYJO F, BRANcAccIo D, BARDIN T, Milano, Wichtig
Editore, 1989, pp. 111—1 18
26. Coooi 0, MAIORANO E, BRAIDOTII P, DELL'ORTO P, VIALE G:
Beta-2 microglobulin amyloidosis in synovial membranes: Histopa-
thology, immunocytochemistry and electron microscopy, in Dialy-
sis Amyloidosis, edited by GEYJO F, BRANCACCIO D, BARDIN T,
Milano, Wichtig Editore, 1989, p. 57—78
27. HYAFIL F, STROMINGER JL: Dissociation and exchange of the
132-microglobulin subunit of HLA-A and HLA-B antigens. Proc
Nat! Acad Sci USA 76:5834—5838, 1979
28. BO5TEL F, HAUGER W: ssmTcNanokolloid: Klinische Ergebnisse
im Einsatz eines neuen Entzundungsmarkers. Fortschr Róntgenstr
149:648—653, 1988
29. Effects of membranes in long-term hemodialysis (fig. 24—26), in
Combined report on regular dialysis and transplantation in Europe,
XVII, 1986, presented at the XXIVth Congress of the Eur Dial
Transplantation Assoc, Berlin (West) 1987
30. VAN YPERSELE DE STRIH0u C, HONHON B, VANDEBROUCKE JM,
HUAUX JP, NOEL H, MALDAGUE B: L'amylose du dialyse, in
Actualites Nephrologiques Hospital Necker, edited by Gruenfeld J,
Paris, Flammarion Medecine-Sciences, 1987, pp. 371—389
